Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | WNT1 | P04628 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.31 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24369858 | 1.00 | BACE1 (0.35) | BACE1WNT1GSK3BDYRK1AACACB | |
| SCHEMBL25098686 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL25099319 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL25098954 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL25098685 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL25098675 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL24369857 | 0.88 | WNT1 (0.32) | WNT1GSK3BDYRK1ACCR3TP53 | |
| SCHEMBL25098949 | 0.77 | WNT1 (0.33) | WNT1GSK3BDYRK1ATP53MDM2 | |
| SCHEMBL24820178 | 0.74 | PIK3CD (0.37) | WNT1GSK3BDYRK1ATP53MDM2 | |
| SCHEMBL23374669 | 0.74 | PIK3CD (0.37) | WNT1GSK3BDYRK1ATP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | BACE1 2152/4885WNT1 2858/4885GSK3B 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.